In Brief: IGI
This article was originally published in The Rose Sheet
Executive Summary
IGI: Novasome lipid microvesicle manufacturer's first quarter consumer product sales grow about 38% to $1.2 mil., representing 13% of consolidated sales versus 7% of sales a year ago, the company said April 25. The firm attributed the improvement to an increase in product sales to Estee Lauder. The increase was also due to initial delivery sales of IGI's Nova Skin line to Glaxo Wellcome. Glaxo gained marketing rights to Nova Skin in January and relaunched it under the WellSkin brand, IGI said ("The Rose Sheet" Jan. 13, p. 2). Overall revenues climbed 9.9% to $9.5 mil., while net income advanced 31.5% to $363,000. The remainder of IGI's sales are generated from its animal health segment...
|
IGI: Novasome lipid microvesicle manufacturer's first quarter consumer product sales grow about 38% to $1.2 mil., representing 13% of consolidated sales versus 7% of sales a year ago, the company said April 25. The firm attributed the improvement to an increase in product sales to Estee Lauder. The increase was also due to initial delivery sales of IGI's Nova Skin line to Glaxo Wellcome. Glaxo gained marketing rights to Nova Skin in January and relaunched it under the WellSkin brand, IGI said ("The Rose Sheet" Jan. 13, p. 2). Overall revenues climbed 9.9% to $9.5 mil., while net income advanced 31.5% to $363,000. The remainder of IGI's sales are generated from its animal health segment.... |